Methods for inducing in vivo tolerance
The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue.
1. A method for treating GVHD, the method comprising administering an agonistic anti-BTLA antibody that does not deplete T cells that express BTLA to a subject at substantially the same time the subject is exposed to a graft.
2. The method of claim 1 , wherein the antibody is administered at the same time as the graft exposure.
3. The method of claim 1 , wherein the antibody is administered before the graft exposure.
4. The method of claim 1 , wherein the antibody is administered within one week of the graft exposure.
5. The method of claim 1 , wherein the antibody expands a pre-existing Treg cell population.
6. The method of claim 1 , wherein the antibody is administered once.
7. The method of claim 6 , wherein the antibody is administered once, and at the time of graft exposure.
8. A method for inducing in vivo tolerance to a foreign bone marrow in a subject, the method comprising administering an agonistic anti-BTLA antibody to a subject undergoing a bone marrow transplant at substantially the same time as the foreign tissue exposure.
9. The method of claim 8 , wherein the immune system of the subject is not systemically suppressed.
10. The method of claim 8 , wherein the antibody does not deplete T cells.
11. The method of claim 8 , wherein the antibody is administered at the same time as the foreign tissue exposure.
12. The method of claim 8 , wherein the antibody is administered before the foreign tissue exposure.
13. The method of claim 8 , wherein the antibody is administered within one week of the foreign tissue exposure.
14. The method of claim 8 , wherein the antibody expands a pre-existing Treg cell population.
15. The method of claim 8 , wherein the antibody is administered once.
16. The method of claim 15 , wherein the antibody is administered once, and at the time of foreign tissue exposure.
17. A method for treating GVHD, the method comprising administering an agonistic anti-BTLA antibody to a subject undergoing a bone marrow transplant at substantially the same time the subject is exposed to a graft.
18. The method of claim 17 , wherein the antibody does not deplete T cells.
19. The method of claim 17 , wherein the antibody is administered at the same time as the graft exposure.
20. The method of claim 17 , wherein the antibody is administered before the graft exposure.
21. The method of claim 17 , wherein the antibody is administered within one week of the graft exposure.
22. The method of claim 17 , wherein the antibody expands a pre-existing Treg cell population.
23. The method of claim 17 , wherein the antibody is administered once.
24. The method of claim 23 , wherein the antibody is administered once, and at the time of graft exposure.
25. A method for treating GVHD, the method comprising administering a single dose of an agonistic anti-BTLA antibody to a subject at substantially the same time the subject is exposed to a graft.
26. The method of claim 25 , wherein the antibody does not deplete T cells.
27. The method of claim 25 , wherein the antibody is administered at the same time as the graft exposure.
28. The method of claim 25 , wherein the antibody is administered before the graft exposure.
29. The method of claim 25 , wherein the antibody is administered within one week of the graft exposure.